{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:47:29Z","timestamp":1759564049250},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T00:00:00Z","timestamp":1691798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s12325-023-02595-x","type":"journal-article","created":{"date-parts":[[2023,8,12]],"date-time":"2023-08-12T03:18:38Z","timestamp":1691810318000},"page":"4127-4133","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy)"],"prefix":"10.1007","volume":"40","author":[{"given":"Sateria R.","family":"Venable","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayman","family":"Al-Hendy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,12]]},"reference":[{"key":"2595_CR1","doi-asserted-by":"publisher","first-page":"1003605","DOI":"10.3389\/fmed.2022.1003605","volume":"9","author":"LC Cheng","year":"2022","unstructured":"Cheng LC, Li HY, Gong QQ, Huang CY, Zhang C, Yan JZ. Global, regional, and national burden of uterine fibroids in the last 30 years: estimates from the 1990 to 2019 global burden of disease study. Front Med (Lausanne). 2022;9:1003605.","journal-title":"Front Med (Lausanne)"},{"key":"2595_CR2","volume":"14","author":"SG Datir","year":"2022","unstructured":"Datir SG, Bhake A. Management of uterine fibroids and its complications during pregnancy: a review of literature. Cureus. 2022;14: e31080.","journal-title":"Cureus"},{"key":"2595_CR3","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/IJWH.S133212","volume":"9","author":"MJ Fuldeore","year":"2017","unstructured":"Fuldeore MJ, Soliman AM. Patient-reported prevalence and symptomatic burden of uterine fibroids among women in the United States: findings from a cross-sectional survey analysis. Int J Womens Health. 2017;9:403\u201311.","journal-title":"Int J Womens Health"},{"key":"2595_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"2595_CR5","doi-asserted-by":"publisher","first-page":"1045783","DOI":"10.3389\/fphar.2022.1045783","volume":"13","author":"N Sefah","year":"2022","unstructured":"Sefah N, Ndebele S, Prince L, et al. Uterine fibroidscauses, impact, treatment, and lens to the African perspective. Front Pharmacol. 2022;13:1045783.","journal-title":"Front Pharmacol"},{"key":"2595_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000880","author":"S Lee","year":"2023","unstructured":"Lee S, Stewart EA. New treatment options for nonsurgical management of uterine fibroids. Curr Opin Obstet Gynecol. 2023. https:\/\/doi.org\/10.1097\/GCO.0000000000000880.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"2595_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajog.2013.08.008","volume":"210","author":"HM Eltoukhi","year":"2014","unstructured":"Eltoukhi HM, Modi MN, Weston M, Armstrong AY, Stewart EA. The health disparities of uterine fibroid tumors for African American women: a public health issue. Am J Obstet Gynecol. 2014;210:194\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"2595_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/ijgo.13102","volume":"149","author":"E Giuliani","year":"2020","unstructured":"Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020;149:3\u20139.","journal-title":"Int J Gynaecol Obstet"},{"key":"2595_CR9","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.3390\/jcm10225335","volume":"10","author":"OS Madueke-Laveaux","year":"2021","unstructured":"Madueke-Laveaux OS, Elsharoud A, Al-Hendy A. What we know about the long-term risks of hysterectomy for benign indication-a systematic review. J Clin Med. 2021;10:5335.","journal-title":"J Clin Med"},{"key":"2595_CR10","doi-asserted-by":"crossref","unstructured":"Management of symptomatic uterine leiomyomas: ACOG practice bulletin, number 228. Obstet Gynecol. 2021;137:e100\u2013e15","DOI":"10.1097\/AOG.0000000000004401"},{"key":"2595_CR11","unstructured":"ORIAHNN. Full prescribing information. North Chicago IAI."},{"key":"2595_CR12","unstructured":"Myfembree. Full prescribing information. Brisbane CMS, Inc. 2023."},{"key":"2595_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1056\/NEJMoa2008283","volume":"384","author":"A Al-Hendy","year":"2021","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Treatment of uterine fibroid symptoms with relugolix combination therapy. N Engl J Med. 2021;384:630\u201342.","journal-title":"N Engl J Med"},{"key":"2595_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1097\/AOG.0000000000004988","volume":"140","author":"A Al-Hendy","year":"2022","unstructured":"Al-Hendy A, Lukes AS, Poindexter AN 3rd, et al. Long-term relugolix combination therapy for symptomatic uterine leiomyomas. Obstet Gynecol. 2022;140:920\u201330.","journal-title":"Obstet Gynecol"},{"key":"2595_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1097\/AOG.0000000000003141","volume":"133","author":"Y Osuga","year":"2019","unstructured":"Osuga Y, Enya K, Kudou K, Tanimoto M, Hoshiai H. Oral Gonadotropin-releasing hormone antagonist relugolix compared with leuprorelin injections for uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2019;133:423\u201333.","journal-title":"Obstet Gynecol"},{"key":"2595_CR16","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40265-022-01790-4","volume":"82","author":"YY Syed","year":"2022","unstructured":"Syed YY. Relugolix\/estradiol\/norethisterone (norethindrone) acetate: a review in symptomatic uterine fibroids. Drugs. 2022;82:1549\u201356.","journal-title":"Drugs"},{"key":"2595_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2014.982246","volume":"31","author":"SS Singh","year":"2015","unstructured":"Singh SS, Belland L. Contemporary management of uterine fibroids: focus on emerging medical treatments. Curr Med Res Opin. 2015;31:1\u201312.","journal-title":"Curr Med Res Opin"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02595-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02595-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T02:03:57Z","timestamp":1696385037000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02595-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,12]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2595"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02595-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,12]]},"assertion":[{"value":"15 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2023","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article was revised due to update in funding note.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethics Guidelines"}},{"value":"Ayman Al-Hendy has consulted for AbbVie, Bayer, Myovant Sciences, and ObsEva; received research support from the National Institutes of Health (R01 ES 028615\u201301, R01HD 087417, R01 HD 094378, R01 HD 094380, R01 HD 10036701, U54 MD 007602); and holds a patent for methods for novel diagnostics and therapeutics for uterine sarcoma (US patent no. 9,790,562 B2). Sateria Venable has consulted for AbbVie, Bayer, Myovant Sciences and ObsEva.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}